UBS raised the firm’s price target on 10x Genomics (TXG) to $14 from $13 and keeps a Neutral rating on the shares. While 10x Genomics posted a quarterly beat and guidance above expectations, the muted demand environment is persisting, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target raised to $15 from $13 at JPMorgan
- 10x Genomics price target raised to $19 from $16 at Canaccord
- Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks
- 10x Genomics price target raised to $17 from $15 at Barclays
- 10x Genomics: Hold Rating Amid Resilience and Challenges in U.S. Academic and Government Sectors